The antinociceptive effect of acetylsalicylic acid is differently affected by a CB1 agonist or antagonist and involves the serotonergic system in rats

Life Sciences

Volumn 86, Issue 13-14, 2010, Pages 510-517

  Ruggieri, Valentina ^a   Vitale, Giovanni ^a   Filaferro, Monica ^a   Frigeri, Claudio ^a   Pini, Luigi A ^a   Sandrini, Maurizio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

5 HT2 receptors; Acetylsalicylic acid; CB1 receptor agonist and antagonist; Central pain; Rat; Serotonin (5 HT)

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ACETYLSALICYLIC ACID; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; DEXANABINOL; RIMONABANT; SEROTONIN; SEROTONIN 2 RECEPTOR; SR 14171A; UNCLASSIFIED DRUG; ANALGESIC AGENT; CANNABINOID 1 RECEPTOR; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; SEROTONIN TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; FRONTAL CORTEX; LOW DRUG DOSE; MALE; NONHUMAN; PAIN THRESHOLD; RAT; RECEPTOR AFFINITY; RECEPTOR DENSITY; SEROTONINERGIC SYSTEM; WISTAR RAT; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; FRONTAL LOBE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM;

RATTUS;

ANALGESICS; ANIMALS; ASPIRIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FRONTAL LOBE; MALE; PIPERIDINES; PYRAZOLES; RATS; RECEPTOR, CANNABINOID, CB1; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 77950552027     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2010.02.006     Document Type: Article

References (44)

1. 2 receptors and the endocannabinoid system for the treatment of pain. Brain Research Reviews 2009, 60(1):255-266.
2. Anikwue R., Huffman J.W., Martin Z.L., Welch S.P. Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration. Journal of Pharmacology and Experimental Therapeutics 2002, 303:340-346.
3. Ates M., Hamza K., Seidel C.E., Kotalla C., Ledent, Gühring H. Intrathecally applied flurbiprofen produces an endocannabinoid-dependent antinociception in the rat formalin test. European Journal of Neuroscience 2003, 17:597-604.
4. Bambico F.R., Katz N., Debonnel G., Gobbi G. Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. Journal of Neuroscience 2007, 27(43):11700-11711.
5. Bensemana D., Gascon A.L. Relationship between analgesia and turnover of brain biogenic amines. Canadian Journal of Physiology and Pharmacology 1978, 56(5):721-730.
6. Best A.R., Regehr W.G. Serotonin evokes endocannabinoid release and retrogradely suppresses excitatory synapses. Journal of Neuroscience 2008, 28(25):6508-6515.
7. Björkman R. Central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol. Acta Anaesthesiology 1995, 39(103):7-43.
8. Bloom A.S., Dewey W.L., Harris L.S., Brosius K.K. 9-nor-9beta-hydroxyhexahydrocannabinol, a cannabinoid with potent antinociceptive activity: comparisons with morphine. Journal of Pharmacology and Experimental Therapeutics 1977, 200:263-270.
9. Chaperon F., Thiebot M.H. Behavioral effects of cannabinoid agents in animals. Critical Reviews in Neurobiology 1999, 13:243-281.
10. de Leval X., Delarge J., Somers F., de Tullio P., Henrotin Y., Pirotte B., Dogne J.M. Recent advances in inducible cyclooxygenase (COX-2) inhibition. Current Medicinal Chemistry 2000, 10:1041-1062.
11. Freund T.F., Katona I., Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiological Reviews 2003, 83(3):1017-1066.
12. Grossi G., Bargossi A., Sprovieri G., Benagozzi V., Pasquale R. Full automation of serotonin determination by column switching and HPLC. Chromatographia 1990, 30:61-68.
13. Gühring H., Hamza M., Sergejeva M., Ates M., Kotalla C.E., Ledent C., Brune K. A role for endocannabinoids in indomethacin-induced spinal antinociception. European Journal of Pharmacology 2002, 454:153-163.
14. Guindon J., De Léan A., Beaulieu P. Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain. Pain 2006, 121:85-93.
15. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., De Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. Journal of Neuroscience 1991, 11:563-583.
16. Hohmann N., Tsou K., Walker J.M. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. Journal of Neurophysiology 1999, 81:575-583.
17. Hunskaar S., Hole K. The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain 1987, 30(1):103-114.
18. 3H]ligand for serotonin receptor binding sites. Molecular Pharmacology 1989, 21:301-309.
19. Lichtman A.H., Martin B.R. Spinal and supraspinal components of cannabinoid-induced antinociception. Journal of Pharmacology and Experimental Therapeutics 1991, 258:517-523.
20. Mallet C., Daulhac L., Bonnefont J., Ledent C., Etienne M., Chapuy E., Libert F., Eschalier A. Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia. Pain 2008, 139:190-200.
21. 1 in distinct neuronal subpopulations in the adult mouse forebrain. European Journal of Neuroscience 1999, 11(12):4213-4225.
22. McCormack K. The spinal actions of nonsteroidal anti-inflammatory drugs and the dissociation between their anti-inflammatory and analgesic effects. Drugs 1994, 47(S5):28-47.
23. McMahon L.R., Koek W. Differences in the relative potency of SR141716A and AM251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice. European Journal of Pharmacology 2007, 569(1-2):70-76.
24. Millan M.J. Descending control of pain. Progress in Neurobiology 2002, 66:355-474.
25. Miranda H.F., Pinardi G. Lack of effect of naltrindole on the spinal synergism of morphine and non-steroidal anti-inflammatory drugs (NSAIDS). Journal of Physiology and Pharmacology 2009, 60(2):71-76.
26. Molina-Holgado F., Molina-Holgado E., Leret M.L., Gonzàlez M.I., Reader T.A. Distribution of indolamines and [3H]paraoxetine binding in rat brain regions following acute or perinatal Δ9-tetrahydrocannabinol treatments. Neurochemical Research 1993, 18:1183-1191.
27. Moss D.E., Johnson R.L. Tonic analgesic effects of delta 9-tetrahydrocannabinol as measured with the formalin test. European Journal of Pharmacology 1980, 61:313-315.
28. 1 receptors. European Journal of Pharmacology 2006, 53:280-281.
29. Palazzo E., de Novellis V., Petrosino S., Marabese I., Vita D., Giordano C., Di Marzo V. Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system. European Journal of Neuroscience 2006, 24:2011-2020.
30. Pini L.A., Sandrini M., Vitale G. Involvement of brain serotonergic system in the antinociceptive action of acetylsalicylic acid in the rat. Inflammation Research 1995, 44(1):30-35.
31. Pini L.A., Sandrini M., Vitale G. The antinociceptive action of paracetamol is associated with changes in the srotonergic system in the rat brain. European Journal of Pharmacology 1996, 308:31-40.
32. 1 receptor reverse agonist and neutral antagonist: Effects of food intake, food reinforced behavior and food aversion. Physiology & Behavior 2007, 91:283-288.
33. Sandrini M., Vitale G., Dondi M., Pini L.A. Effect of acetylsalicylic acid on serotonin brain receptor subtypes. General Pharmacology 1995, 26(4):737-741.
34. Sandrini M., Vitale G., Pini L.A. Central antinociceptive acticvity of acetylsalicylic acid is modulated by brain serotonin receptor subtypes. Pharmacology 2002, 65(4):193-197.
35. Shearman L.P., Rosko K.M., Fleischer R., Wang J., Xu S., Tong X.S., Rocha B.A. Antidepressant-like and anorectic effects of the cannabinoid receptor inverse agonist AM251 in mice. Behavioral Pharmacology 2003, 14(8):573-582.
36. Snedecor, G.W., Cochran, W.J. Statistical Methods. In: Iowa State University Press, Ames, Iowa 298, 1980.
37. Thiemann G., Watt C.A., Ledent C., Molleman A., Hasenöhrl R.U. Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain. Behavioural Brain Research 2009, 200(1):60-67.
38. Tzavara E.T., Davis R.J., Perry K.W., Li X., Salhoff C., Bymaster F.P., Witkin J.M., Nomikos G.G. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. British Journal of Pharmacology 2003, 138(4):544-553.
39. Ulugöl A., Ozyigit F., Yesilyurt O., Dogrul A. The additive antinociceptive interaction between WIN 55, 212-2, a cannabinoid agonist, and ketorolac. Anesthesia and Analgesia 2006, 102(2):443-447.
40. Vane J.R., Botting R.M. Inflammation and the mechanism of action of anti-inflammatory drugs. Inflammation Research 1987, 1:89-96.
41. Vane J.R., Botting R.M. New insights into the mode of action of anti-inflammatory drugs. Inflammation Research 1995, 44:1-10.
42. Vitale G., Pini L.A., Ottani A., Sandrini M. Effect of acetylsalicylic acid on formalin test and on serotonin system in the rat brain. General Pharmacology 1998, 31(5):753-758.
43. Walker J.M., Huang S.M. Cannabinoid analgesia. Pharmacology & Therapeutics 2002, 95:127-135.
44. Walker J.M., Huang S.M., Strangman N.M., Tsou K., Sanudo-Pena M.C. Pain modulation by release of the endogenous cannabinoid anandamide. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:12198-12203.